Nicholas covers all four phase 3 TRIUMPH trials of Eli Lilly's triple-hormone drug, why cross-trial comparisons mislead, the new skin side effect, and the filing timeline.
Read the full post: Retatrutide's phase 3 TRIUMPH results: what they showed and what comes next
In this episode
- 00:00 Cold open and intro
- 00:39 What retatrutide is
- 00:50 The four TRIUMPH trials
- 01:27 How it compares with tirzepatide and semaglutide
- 01:49 Side effects, including dysesthesia
- 02:15 Why the diabetes numbers look smaller
- 02:45 Filing timeline and research vials
- 03:10 Wrap-up and Amino Club code
Peptides covered
Tools and deals
- Free reconstitution and dosing calculator: mypeps.info/calculator
- Amino Club: 40% off with code MYPEPSINFO at aminoclub.com
Sources
- https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial
- https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
- https://www.biospace.com/drug-development/lillys-retatrutide-scores-triple-trial-triumph-with-26-weight-loss-but-new-safety-signal-emerges
- https://clinicaltrials.gov/study/NCT06662383
- https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
- Full source list in the blog post.
Educational information only, not medical advice. Talk to a licensed clinician before starting, stopping or changing any medication. Research-grade peptides are not FDA-approved drugs.